Please assess the completion status of the following clinical trial:

Trial Title: Boost rTMS for Auditory Verbal Hallucinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form~2. Stated willingness to comply with all study procedures and availability for the duration of the study~3. Male or female, aged 18 to 65~4. Diagnosed with Diagnostic and Statistical Manual (DSM) V diagnosis of schizophrenia (295.90), schizoaffective disorder (295.70), or brief psychotic disorder (298.80), prone to AVH in the acute phases of the disorder~5. Willing to adhere to the rTMS regimen~6. No antipsychotic medication in the last two weeks prior to the start of the study as well as no antipsychotic medication during participation in the study~7. Agreement to adhere to Lifestyle Considerations throughout study duration~Exclusion Criteria:~1. Current use of antipsychotic medication within the last 2 weeks~2. Electroconvulsive therapy or rTMS within three months (see the TMS screening questionnaire)~3. History of seizures~4. Presence of implanted electronic device or metal implant in the head and neck region (DBS, cochlear implant, etc.)~5. Pregnancy, as assessed with a pregnancy test prior to every MRI measurement, or lactation~6. Any active general medical condition or central nervous system disease which can affect cognition or response to treatment~7. Treatment with another investigational drug or other intervention within 2 weeks~8. Current diagnosis of delirium, dementia, or amnestic amnesiac disorder; Diagnosis of mental retardation; Current (within the past three months) diagnosis of active substance dependence, or active substance abuse within the past week as indicated by self-report.~9. Patients who are cognitively impaired and are thus not able to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- real transcranial magnetic stimulation (Type: EXPERIMENTAL): In the treatment arm, patients will receive 1Hz of repetitive transcranial magnetic stimulation (rTMS) over the left Sylvian parietal temporal area (area Spt) four times on 1 day (1 pulse/second and a total of 1'000 pulses: 16 minutes' protocol at 100 % of motor threshold modified based on Hoffman et al.,1999). Area Spt will be localized via baseline structural imaging and our Localite TMS navigation system.
- sham transcranial magnetic stimulation (Type: PLACEBO_COMPARATOR): In the comparator arm, patients will receive no stimulation. The TMS coil adjusted to the patients head will not be plugged into the TMS machine and can thus not have an effect on the brain. Yet, patients will hear the same noises from a coil that is plugged in, see the TMS machine running, and area Spt localized via baseline structural imaging and our Localite TMS navigation system.

Based on this trial design, predict the completion outcome and termination type (if applicable).